38 completed, 4 terminated, 2 recruiting, 1 unknown. 33 Phase 1, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 33 | Completed 30, Terminated 2, Recruiting 1 |
| Phase 2 | 12 | Completed 8, Terminated 2, Recruiting 1, Unknown 1 |
Follow Enanta Pharmaceuticals, Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus zelicapavir, Placebo - RSV Infection, RSV | Phase 2 | Recruiting | Enanta Pharmaceuticals, Inc | 150 | 2026-07-09 | 2026-07-20 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults EDP-978, Placebo - Chronic Inducible Urticaria, Chronic Spontaneous Urticaria | Phase 1 | Recruiting | Enanta Pharmaceuticals, Inc | 98 | 2026-04-01 | 2026-04-21 |
| A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants EDP-323, Midazolam, Caffeine - RSV Infection, Drug Drug Interaction | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 24 | 2025-03-13 | 2025-07-01 |
| A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323. EDP-323, Itraconazole, carbamazepine - RSV Infection, Drug Drug Interaction (DDI) | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 48 | 2025-01-27 | 2025-07-01 |
| A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults zelicapavir (therapeutic dose), zelicapavir (supratherapeutic dose), Placebo - RSV Infection, QTc Interval | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 72 | 2024-07-15 | 2025-07-28 |
| A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model EDP-323 Dose Regimen 1, EDP-323 Dose Regimen 2, Placebo - RSV Infection | Phase 2 | Completed | Enanta Pharmaceuticals, Inc | 142 | 2023-11-20 | 2025-10-07 |
| A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications. EDP-938, Placebo - RSV Infection | Phase 2 | Completed | Enanta Pharmaceuticals, Inc | 187 | 2022-11-29 | 2026-08-19 |
| A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19 EDP-235, Placebo - COVID-19 | Phase 2 | Completed | Enanta Pharmaceuticals, Inc | 231 | 2022-11-10 | 2024-08-19 |
| Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects EDP-235, Midazolam, Rosuvastatin - COVID-19 | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 24 | 2022-10-06 | 2023-04-27 |
| Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects. EDP-235, Itraconazole, Carbamazepine - COVID-19 | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 36 | 2022-10-06 | 2023-04-27 |
| A Study of EDP-323 in Healthy Subjects EDP-323, Placebo - RSV Infection | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 82 | 2022-09-29 | 2023-09-01 |
| A Study to Evaluate EDP 938 Regimens in Children With RSV EDP-938, Placebo - Respiratory Syncytial Virus (RSV) | Phase 2 | Completed | Enanta Pharmaceuticals, Inc | 99 | 2022-04-26 | 2025-07-28 |
| A Study of EDP-235 in Healthy Subjects EDP-235, Placebo - SARS CoV 2 Infection | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 72 | 2022-01-28 | 2022-08-19 |
| A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION. EDP-721, Placebo (Part 1), EDP-721 (Part 2) - Chronic Hepatitis B Virus Infection | Phase 1 | Terminated | Enanta Pharmaceuticals, Inc | 26 | 2021-08-02 | 2022-02-14 |
| Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract EDP-938, Placebo - Respiratory Syncytial Virus Infections | Phase 2 | Terminated | Enanta Pharmaceuticals, Inc | 9 | 2021-07-07 | 2024-08-22 |
| Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects EDP-938 - Respiratory Syncytial Virus (RSV) | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 8 | 2021-05-28 | 2022-03-23 |
| Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects EDP-938, Fluconazole - RSV Infection | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 24 | 2021-03-12 | 2021-05-04 |
| Drug-Drug Interaction Study Between EDP-514, Itraconazole, Carbamazepine, and Quinidine in Healthy Subjects EDP-514, Itraconazole, Carbamazepin - Hepatitis B | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 72 | 2020-11-05 | 2021-08-16 |
| A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment EDP-514, Placebo - Chronic HBV Infection | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 25 | 2020-09-09 | 2022-01-11 |
| A Study of EDP-297 in Healthy Subjects EDP-297, Placebo - NASH - Nonalcoholic Steatohepatitis With Liver Fibrosis | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 82 | 2020-09-08 | 2021-10-29 |
Showing 20 of 45. Sign in to see all of them.
Respiratory Syncytial Virus Infections (14) · Non-alcoholic Fatty Liver Disease (6) · COVID-19 (4) · Hepatitis B (4) · Hepatitis C (3) · Chronic Inducible Urticaria (1) · Chronic Urticaria (1) · Communicable Diseases (1) · Community-Acquired Pneumonia (1) · Fatty Liver (1) · Hepatitis B, Chronic (1) · Infections (1) · Liver Cirrhosis, Biliary (1) · Soft Tissue Infections (1)
EDP-938 (11) · EDP-305 (6) · Quinidine (5) · EDP-235 (4) · Itraconazole (4) · Midazolam (4) · Rosuvastatin Calcium (4) · Caffeine (3) · Carbamazepine (3) · Fluconazole (3) · EDP-239 (2) · Rifampin (2) · Contraceptives, Oral (1) · Cyclosporine (1) · Dabigatran (1)
United States (37) · United Kingdom (7) · Argentina (5) · Canada (5) · Germany (5) · New Zealand (5) · Poland (4) · South Africa (4) · Spain (4) · Taiwan (4) · France (3) · Mexico (3) · Australia (2) · Belgium (2) · Brazil (2)
Daniel Dickerson, MD (2) · Edward Gane, MD (1) · Nathalie Adda, MD (1) · Scott Rottinghaus, MD (1) · Theresa T Pham, MD (1) · Thomas L Hunt, MD, PhD (1)
PMID 27503640, PMID 27503644, PMID 34740705, PMID 35172056, PMID 36369848, PMID 39441691
2019 (1)